D
vTv Therapeutics Inc.
VTVT
$22.74
$7.8953.13%
D
Sell
3/7/2025Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 3/7/2025 due to an increase in the total return index, valuation index and volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 3/7/2025 due to an increase in the total return index, valuation index and volatility index.
E
Sell
2/20/2025Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 2/20/2025 due to a decline in the valuation index.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 2/20/2025 due to a decline in the valuation index.
D
Sell
2/5/2025Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 2/5/2025 due to an increase in the total return index, volatility index and growth index.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 2/5/2025 due to an increase in the total return index, volatility index and growth index.
E
Sell
1/21/2025Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index and total return index.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 1/21/2025 due to a decline in the volatility index and total return index.
D
Sell
1/6/2025Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 1/6/2025 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$2.1292 to -$1.831, EBIT increased 9.07% from -$7.16M to -$6.51M, and operating cash flow increased 4.62% from -$6.73M to -$6.42M.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 1/6/2025 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$2.1292 to -$1.831, EBIT increased 9.07% from -$7.16M to -$6.51M, and operating cash flow increased 4.62% from -$6.73M to -$6.42M.
E
Sell
10/10/2024Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and total return index.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 10/10/2024 due to a decline in the volatility index and total return index.
D
Sell
9/25/2024Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 9/25/2024 due to an increase in the volatility index.
E
Sell
9/10/2024Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 9/10/2024 due to a decline in the volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 9/10/2024 due to a decline in the volatility index.
D
Sell
5/2/2024Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 5/2/2024 due to an increase in the total return index and volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 5/2/2024 due to an increase in the total return index and volatility index.
E
Sell
4/12/2024Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index and valuation index.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 4/12/2024 due to a decline in the volatility index and valuation index.
D
Sell
3/27/2024Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 3/27/2024 due to an increase in the growth index and volatility index. Earnings per share increased from -$3.2664 to -$1.6681, operating cash flow increased 39.72% from -$4.83M to -$2.91M, and EBIT increased 12.31% from -$5.37M to -$4.71M.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 3/27/2024 due to an increase in the growth index and volatility index. Earnings per share increased from -$3.2664 to -$1.6681, operating cash flow increased 39.72% from -$4.83M to -$2.91M, and EBIT increased 12.31% from -$5.37M to -$4.71M.
E
Sell
10/5/2023Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 10/5/2023 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0552 to -$0.069, operating cash flow declined 19.38% from -$5.17M to -$6.17M, and EBIT declined 7.72% from -$7.43M to -$8M.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 10/5/2023 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0552 to -$0.069, operating cash flow declined 19.38% from -$5.17M to -$6.17M, and EBIT declined 7.72% from -$7.43M to -$8M.
D
Sell
3/22/2023Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 3/22/2023 due to a decline in the volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 3/22/2023 due to a decline in the volatility index.
D
Sell
3/7/2023Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 3/7/2023 due to a large increase in the growth index. Operating cash flow increased 22.06% from -$8.83M to -$6.88M.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 3/7/2023 due to a large increase in the growth index. Operating cash flow increased 22.06% from -$8.83M to -$6.88M.
D
Sell
11/17/2022Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/17/2022 due to a substantial decline in the growth index and solvency index. Operating cash flow declined 1,350.28% from $706 to -$8.83M, EBIT declined 41.27% from -$4.03M to -$5.69M, and earnings per share declined from -$0.0448 to -$0.0529.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/17/2022 due to a substantial decline in the growth index and solvency index. Operating cash flow declined 1,350.28% from $706 to -$8.83M, EBIT declined 41.27% from -$4.03M to -$5.69M, and earnings per share declined from -$0.0448 to -$0.0529.
D
Sell
5/16/2022Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
vTv Therapeutics Inc. (VTVT) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
E
Sell
5/13/2022Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index. Debt to equity increased from -0.05 to -0.02, and the quick ratio declined from 1.61 to 0.96.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index. Debt to equity increased from -0.05 to -0.02, and the quick ratio declined from 1.61 to 0.96.
D
Sell
5/5/2022Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and growth index.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and growth index.
E
Sell
4/20/2022Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 04/20/2022.
vTv Therapeutics Inc. (VTVT) was downgraded to E+ from D- on 04/20/2022.
D
Sell
3/30/2022Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 3/30/2022 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 593.01% from -$1.6M to -$11.11M, earnings per share declined from -$0.0178 to -$0.1056, and total revenue declined 99.7% from $3M to $9.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 3/30/2022 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 593.01% from -$1.6M to -$11.11M, earnings per share declined from -$0.0178 to -$0.1056, and total revenue declined 99.7% from $3M to $9.
D
Sell
11/10/2021Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and solvency index. Total revenue increased 33,233.33% from $9 to $3M, the quick ratio increased from 2.17 to 3.74, and EBIT increased 65.67% from -$4.67M to -$1.6M.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and solvency index. Total revenue increased 33,233.33% from $9 to $3M, the quick ratio increased from 2.17 to 3.74, and EBIT increased 65.67% from -$4.67M to -$1.6M.
D
Sell
11/8/2021Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index and volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
9/7/2021Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 9/7/2021 due to a decline in the volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 9/7/2021 due to a decline in the volatility index.
D
Sell
8/6/2021Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 8/6/2021 due to a significant increase in the solvency index, total return index and growth index. Earnings per share increased from -$0.0751 to -$0.0104, the quick ratio increased from 1.65 to 2.17, and operating cash flow increased 24.55% from -$5.3M to -$4M.
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 8/6/2021 due to a significant increase in the solvency index, total return index and growth index. Earnings per share increased from -$0.0751 to -$0.0104, the quick ratio increased from 1.65 to 2.17, and operating cash flow increased 24.55% from -$5.3M to -$4M.
D
Sell
5/1/2020Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index.
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 5/1/2020 due to a significant decline in the efficiency index.
D
Sell
4/15/2020Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 4/15/2020 due to a significant decline in the solvency index and volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 4/15/2020 due to a significant decline in the solvency index and volatility index.
C
Hold
2/24/2020Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D on 2/24/2020 due to a significant increase in the efficiency index, total return index and volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D on 2/24/2020 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
11/5/2019Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 11/5/2019 due to a significant decline in the efficiency index, growth index and total return index. Total revenue declined 99.56% from $1.83M to $8, net income declined 25.19% from -$2.88M to -$3.61M, and earnings per share declined from -$0.1028 to -$0.1281.
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 11/5/2019 due to a significant decline in the efficiency index, growth index and total return index. Total revenue declined 99.56% from $1.83M to $8, net income declined 25.19% from -$2.88M to -$3.61M, and earnings per share declined from -$0.1028 to -$0.1281.
D
Sell
10/11/2019Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 10/11/2019 due to a decline in the total return index.
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 10/11/2019 due to a decline in the total return index.
C
Hold
9/16/2019Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 9/16/2019 due to an increase in the total return index.
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 9/16/2019 due to an increase in the total return index.
D
Sell
8/2/2019Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 8/2/2019 due to a significant increase in the efficiency index, growth index and solvency index. Total revenue increased 98.48% from $921 to $1.83M, and earnings per share increased from -$0.2573 to -$0.1028.
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 8/2/2019 due to a significant increase in the efficiency index, growth index and solvency index. Total revenue increased 98.48% from $921 to $1.83M, and earnings per share increased from -$0.2573 to -$0.1028.
D
Sell
5/7/2019Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 5/7/2019 due to a significant decline in the efficiency index, growth index and total return index. EBIT declined 1,121.37% from -$351 to -$4.29M, earnings per share declined from -$0.1034 to -$0.26, and net income declined 97.53% from -$1.09M to -$2.16M.
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 5/7/2019 due to a significant decline in the efficiency index, growth index and total return index. EBIT declined 1,121.37% from -$351 to -$4.29M, earnings per share declined from -$0.1034 to -$0.26, and net income declined 97.53% from -$1.09M to -$2.16M.
D
Sell
4/25/2019Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 4/25/2019 due to a decline in the volatility index and total return index.
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 4/25/2019 due to a decline in the volatility index and total return index.
C
Hold
2/28/2019Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 2/28/2019 due to a significant increase in the efficiency index, volatility index and total return index. Total capital increased 20.48% from -$5.86M to -$4.66M.
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 2/28/2019 due to a significant increase in the efficiency index, volatility index and total return index. Total capital increased 20.48% from -$5.86M to -$4.66M.
D
Sell
11/14/2018Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 11/14/2018 due to an increase in the growth index, total return index and volatility index. EBIT increased 83.28% from -$8.86M to -$1.48M, earnings per share increased from -$0.3057 to -$0.0647, and total revenue increased 36.47% from $2.47M to $3.38M.
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D on 11/14/2018 due to an increase in the growth index, total return index and volatility index. EBIT increased 83.28% from -$8.86M to -$1.48M, earnings per share increased from -$0.3057 to -$0.0647, and total revenue increased 36.47% from $2.47M to $3.38M.
D
Sell
6/12/2018Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 6/12/2018 due to a large decline in the total return index, efficiency index and volatility index. Total capital declined 42,545% from -$20 to -$8.53M.
vTv Therapeutics Inc. (VTVT) was downgraded to D from D+ on 6/12/2018 due to a large decline in the total return index, efficiency index and volatility index. Total capital declined 42,545% from -$20 to -$8.53M.
D
Sell
3/23/2018Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 3/23/2018 due to a decline in the volatility index.
vTv Therapeutics Inc. (VTVT) was downgraded to D+ from C- on 3/23/2018 due to a decline in the volatility index.
C
Hold
3/7/2018Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 3/7/2018 due to an increase in the volatility index, growth index and total return index.
vTv Therapeutics Inc. (VTVT) was upgraded to C- from D+ on 3/7/2018 due to an increase in the volatility index, growth index and total return index.
D
Sell
2/28/2018Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D- on 2/28/2018 due to a significant increase in the efficiency index, total return index and valuation index.
vTv Therapeutics Inc. (VTVT) was upgraded to D+ from D- on 2/28/2018 due to a significant increase in the efficiency index, total return index and valuation index.
D
Sell
2/7/2018Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 2/7/2018 due to a decline in the volatility index, total return index and valuation index.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 2/7/2018 due to a decline in the volatility index, total return index and valuation index.
D
Sell
1/23/2018Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 1/23/2018 due to an increase in the total return index and volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 1/23/2018 due to an increase in the total return index and volatility index.
D
Sell
11/2/2017Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/2/2017 due to a decline in the efficiency index and valuation index. Total capital declined 44.9% from $24.77M to $13.65M.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 11/2/2017 due to a decline in the efficiency index and valuation index. Total capital declined 44.9% from $24.77M to $13.65M.
D
Sell
9/7/2017Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 9/7/2017 due to an increase in the volatility index.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 9/7/2017 due to an increase in the volatility index.
D
Sell
8/3/2017Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 8/3/2017 due to a large decline in the efficiency index, growth index and volatility index. Total revenue declined 56.67% from $30 to $13, and total capital declined 32.96% from $36.95M to $24.77M.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 8/3/2017 due to a large decline in the efficiency index, growth index and volatility index. Total revenue declined 56.67% from $30 to $13, and total capital declined 32.96% from $36.95M to $24.77M.
D
Sell
2/27/2017Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 2/27/2017 due to a major increase in the efficiency index, growth index and total return index. Operating cash flow increased 10.23% from -$12.73M to -$11.43M, and EBIT increased 1.59% from -$13.53M to -$13.31M.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 2/27/2017 due to a major increase in the efficiency index, growth index and total return index. Operating cash flow increased 10.23% from -$12.73M to -$11.43M, and EBIT increased 1.59% from -$13.53M to -$13.31M.
D
Sell
8/3/2016Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 8/3/2016 due to a noticeable decline in the efficiency index, growth index and valuation index. Total revenue declined 51.6% from $376 to $182, total capital declined 19.7% from $70.65M to $56.73M, and net income declined 15.71% from -$3.85M to -$4.46M.
vTv Therapeutics Inc. (VTVT) was downgraded to D- from D on 8/3/2016 due to a noticeable decline in the efficiency index, growth index and valuation index. Total revenue declined 51.6% from $376 to $182, total capital declined 19.7% from $70.65M to $56.73M, and net income declined 15.71% from -$3.85M to -$4.46M.
D
Sell
8/1/2016Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 8/1/2016 due to an increase in the growth index, total return index and volatility index. Total revenue increased 66.37% from $226 to $376.
vTv Therapeutics Inc. (VTVT) was upgraded to D from D- on 8/1/2016 due to an increase in the growth index, total return index and volatility index. Total revenue increased 66.37% from $226 to $376.
D
Sell
4/1/2016Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E on 04/01/2016.
vTv Therapeutics Inc. (VTVT) was upgraded to D- from E on 04/01/2016.
E
Sell
3/11/2016Downgrade
vTv Therapeutics Inc. (VTVT) was downgraded to E from E+ on 3/11/2016 due to a large decline in the volatility index, solvency index and total return index. The quick ratio declined from 15.97 to 11.4.
vTv Therapeutics Inc. (VTVT) was downgraded to E from E+ on 3/11/2016 due to a large decline in the volatility index, solvency index and total return index. The quick ratio declined from 15.97 to 11.4.
E
Sell
1/4/2016Upgraded
vTv Therapeutics Inc. (VTVT) was upgraded to E+ from E on 1/4/2016 due to a noticeable increase in the solvency index, total return index and valuation index. The quick ratio increased from 0.04 to 15.97, and debt to equity declined from -0.09 to 0.
vTv Therapeutics Inc. (VTVT) was upgraded to E+ from E on 1/4/2016 due to a noticeable increase in the solvency index, total return index and valuation index. The quick ratio increased from 0.04 to 15.97, and debt to equity declined from -0.09 to 0.
E
Sell
10/22/2015None
vTv Therapeutics Inc. (VTVT) was downgraded to E from U on 10/22/2015.
vTv Therapeutics Inc. (VTVT) was downgraded to E from U on 10/22/2015.
NASDAQ
03/17/2025 4:00PM Eastern
Quotes delayed
